Cell Systems’ primary human retinal microvascular endothelial cells (HRMECs, ACBRI 181) and retinal pericytes (ACBRI 183) are optimized for blood-retinal barrier (BRB) modeling, angiogenesis, and retinal disease research, including diabetic retinopathy.
These early passage, antibody-free, cells are validated across high-impact studies for expression of key markers such as CD31, VEGF, Ang-2, CCL2, and NG2, as well as regulatory RNAs like miR-579. Applications include retinal endothelial permeability assays, ECIS barrier function testing, transendothelial resistance, and 3D microvascular-on-chip culture.
With proven performance in co-culture, permeability, inflammation, and gene expression assays, these human retinal endothelial cells and pericytes are ideal for 2D/3D culture, retinal-on-chip platforms, and inner BRB research.
Key Features:
- Early passage cells, Passage 3 (<12 population doublings)
- Antibody-free isolation
- High viability (~85%), 1M cells per vial
- Supports 2D/3D culture, organ-on-chip, and co-culture
- Shipped as frozen vials or proliferating flasks
- Consistency across long-term studies with deep inventory from a single donor lot.
